Omega Therapeutics, Inc. (OMGA): Price and Financial Metrics
GET POWR RATINGS... FREE!
OMGA Stock Price Chart Interactive Chart >
OMGA Price/Volume Stats
| Current price | $2.53 | 52-week high | $31.41 |
| Prev. close | $2.22 | 52-week low | $2.01 |
| Day low | $2.21 | Volume | 334,700 |
| Day high | $2.93 | Avg. volume | 142,320 |
| 50-day MA | $4.65 | Dividend yield | N/A |
| 200-day MA | $13.44 | Market Cap | 121.06M |
Omega Therapeutics, Inc. (OMGA) Company Bio
Omega Therapeutics, Inc. operates as a development-stage biopharmaceutical company. Its OMEGA Epigenomic Programming platform is designed to coopt nature's operating system by harnessing the power of epigenetics, the mechanism for gene control and cell differentiation. The company is developing omega epigenomic controller (OEC) candidates to up-regulate the expression of HNF4a, a transcriptional master regulator as a potential way to restore liver-cell function in patients suffering from chronic liver diseases; to control the expression of genes that have been strongly linked to cell-growth inhibition in patients with diabetes and other conditions to restore the capacity for corneal regeneration; to down-regulate expression of the CXCL1, 2, 3, and IL-8 gene cluster; to control expression of genes implicated in patients with idiopathic pulmonary fibrosis to halt or reverse disease progression and improve disease outcomes; to down-regulate the expression of SFRP1, a protein that inhibits hair growth; and to treat non-small cell lung cancer and small cell lung cancer. It is also developing OTX-2002 to down-regulate c-Myc, an oncogene. The company was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Latest OMGA News From Around the Web
Below are the latest news stories about Omega Therapeutics Inc that investors may wish to consider to help them evaluate OMGA as an investment opportunity.
Omega Therapeutics, Inc. (NASDAQ:OMGA) insiders need another US$316k to breakeven on a US$952k stock purchase even after recent gainsInsiders who bought US$952k worth of Omega Therapeutics, Inc. ( NASDAQ:OMGA ) stock in the last year recovered part of... |
Omega Therapeutics Announces Appointment of Yan Moore, M.D., as Chief Medical OfficerOmega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing™ platform, today announced the appointment of Yan Moore, M.D., as Chief Medical Officer. Dr. Moore has extensive management, research, translational drug development and medical affairs experience across various pharmaceutical and biotechnolog |
Omega Therapeutics (NASDAQ:OMGA) Trading Down 5.4%Shares of Omega Therapeutics Inc (NASDAQ:OMGA) traded down 5.4% on Friday . The company traded as low as $13.85 and last traded at $13.93. 1,079 shares were traded during mid-day trading, a decline of 99% from the average session volume of 97,669 shares. The stock had previously closed at $14.72. A number of analysts have [] |
Brokerages Expect Omega Therapeutics Inc (NASDAQ:OMGA) to Post -$0.57 EPSEquities research analysts predict that Omega Therapeutics Inc (NASDAQ:OMGA) will announce earnings per share of ($0.57) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Omega Therapeutics earnings. The highest EPS estimate is ($0.46) and the lowest is ($0.74). The company is expected to report its next earnings results [] |
The Drug Dogma: Omega Therapeutics Takes Command of Disease with Epigenetic MedicineHeadquartered in Cambridge, Massachusetts, Omega Therapeutics was founded by Flagship Pioneering in 2017 and is currently advancing a broad pipeline of programs that span regenerative medicine, multigenic diseases including immunology, oncology, and select monogenic diseases. With the guidance of founding scientific advisors Rudolf Jaenisch, PhD, and Richard Young, PhD, from MIT and the Whitehead Institute, Omegas mission is to transform medicine in areas of high unmet need with well-defined and circumscribed patient populations. The post The Drug Dogma: Omega Therapeutics Takes Command of Disease with Epigenetic Medicine appeared first on GEN - Genetic Engineering and Biotechnology News . |
OMGA Price Returns
| 1-mo | -32.17% |
| 3-mo | -79.11% |
| 6-mo | -84.66% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -77.67% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...